Trial intelligence / Profile preview

Post-marketing safety surveillance of Scemblix Tablets in resistant or intolerant chronic myeloid leukemia

jRCT2031220191Completed

Sponsor

Novartis

Start

Jul 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1